Results indicate that ISIS 333611 was well-tolerated.
Results Announced for Phase I Trial of ISIS 333611 in SOD1 FALS
A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients with Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutation
The purpose of this study was to test the safety, tolerability, and pharmacokinetics of single doses of ISIS 333611 administered as 12-hour infusions into the spinal fluid.
Four dose levels were evaluated sequentially. Each dose level was studied in a cohort of 8 patients where 6 were randomized to active treatment with ISIS 333611 and 2 were randomized to placebo.
A total of 32 doses were given to 21 individuals with SOD1 ALS (7 subjects were dosed 2 times and 2 subjects were dosed 3 times). Results indicate that ISIS 333611 was well tolerated. No safety or tolerability concerns related to ISIS 333611 were identified. Drug levels in the spinal fluid and blood corresponded well with the predicted levels based on preclinical testing.